自体CAR-T细胞制备失败和/或血液系统恶性肿瘤疗效的早期预测因素
本综述聚焦自体CAR-T治疗血液系统恶性肿瘤时制备失败与临床应答的早期预测因素。文章指出B-ALL患者中15%至40%、B细胞淋巴瘤患者中超过50%仍出现治疗失败,制备失败风险可达25%。综述报告并讨论了可帮助预判制备成功与临床应答的预测因素,包括单采产物质量、疾病进展及既往治疗等。
要点
- B-ALL患者中15%至40%、B细胞淋巴瘤患者中超过50%仍出现治疗失败。
- 自体CAR-T制备失败风险可达25%,单采产物质量、疾病进展和既往治疗为已报告的预测因素。
- 本综述旨在报告并讨论可帮助预判制备成功与临床应答的预测因素。
核心结论
- 本综述旨在报告并讨论有助于预判自体CAR-T制备成功与临床应答的预测因素。
研究设计与样本
- 综述,报告并讨论自体CAR-T细胞制备失败和/或血液系统恶性肿瘤疗效的早期预测因素。
主要发现
- B-ALL患者中15%至40%、B细胞淋巴瘤患者中超过50%仍出现治疗失败。
- 自体CAR-T细胞制备失败风险可达25%。
- 已报告的预测因素包括单采产物质量、疾病进展以及既往治疗。
- 已提出的失败假说包括CD19阴性或阳性复发、CAR-T细胞体内激活和/或扩增不足以及T细胞耗竭。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapies have shown significant benefits in the treatment of hematologic malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma. Despite the therapeutic advances offered by these innovative treatments, failures are still observed in 15% to 40% of patients with B-ALL and >50% of patients with B-cell lymphoma. Several hypotheses have emerged including CD19-negative or -positive relapses, low CAR T-cell activation and/or expansion in vivo, or T-cell exhaustion. To date, in the European Union, CAR T cells granted with marketing authorization are autologous and thus associated with a strong heterogeneity between products. Indeed, the manufacturing of a single batch requires cellular starting material collection by apheresis for each patient, with variable cellular composition, and then challenging pharmaceutical companies to standardize as much as possible the production process. In addition, these cost and time-consuming therapies are associated with a risk of manufacturing failure reaching 25%. Thus, there is a growing need to identify early risk factors of unsuccessful production and/or therapeutic escape. Quality of the apheresis product, pathology progression, as well as previous treatments have been reported as predictive factors of the variability in clinical response. The aim of this review is to report and discuss predictive factors that could help to anticipate the manufacturing success and clinical response.
引用
- Baguet C, Larghero J, Mebarki M, et al. Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies. Blood Adv. 2024. PMID: 38052048. doi:10.1182/bloodadvances.2023011992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。